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Abstract: Insulin-like growth factors (IGFs) play an important role in the regu-
lation of cell growth, differentiation and metabolism. The amount of free, 
biologically active IGFs is regulated by the IGF-binding proteins (IGFBPs). 
IGFBP-3 is the most abundant binding protein and it is known to interact with 
other circulating proteins, including transferrin (Tf). In order to elucidate the 
possible role of IGF/IGFBP-3 in the metabolism of iron, it is necessary to 
isolate IGFBP-3/Tf complexes. Several affinity-based techniques were em-
ployed. The results showed that only the double immunoprecipitation method 
with anti-Tf and anti-IGFBP-3 antibodies selectively separated the complexes 
from other molecular forms, such as monomers, oligomers or fragments of 
IGFBP-3 and Tf. The isolated complexes can now be used to investigate the 
relationship between IGF/IGFBP-3 and iron, both in structural and metabolic 
terms. 
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INTRODUCTION 
Insulin-like growth factors (IGF-I and IGF-II), together with six IGF-binding 
proteins (IGFBP-1 to IGFBP-6), two IGF receptors (IGF-1R and IGF-2R) and in-
sulin and its receptor (IR), comprise a complex system that plays an important 
role in the regulation of cell growth, differentiation and metabolism.1,2 The pivo-
tal role in the regulation of the IGF action have the IGFBPs. The most abundant 
in circulation is IGFBP-3.3 It forms ternary complexes (150 kea) with IGF and an 
acid labile subunit (ALES).4 The ternary complexes cannot cross the vascular 
barrier and they are assumed to be an IGF reservoir, releasing free, biologically 
active IGF upon mitogenic and/or metabolic request of the organism. IGFBP-3 
is, in its native form, a glycoprotein (40–45 kDa), synthesized in the liver paren-
chymal cells.5 Besides its ability to bind and regulate the activity of IGFs, it was 
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also reported that IGFBP-3 has IGF-independent actions, via nuclear IGFBP-3 
receptors,6 and it may bind to other molecules, of which transferring is one.7 
Transferrin (Tf) is a glycoprotein (70–80 kDa) functioning as the main iron 
transporter.8 Regulation of the iron distribution in the organism affects the for-
mation of hemoglobin, the functionality of enzymes (having iron as a cofactor) 
and redox processes.9 
Since the IGF/IGFBP-3 axis promotes anabolic reactions, it would be impor-
tant to investigate its possible role in iron metabolism and the significance of the 
formation of the IGFBP-3/Tf complex. In order to do so, the first step is to isolate 
the complexes from other molecular forms of either IGFBP-3 or Tf, and other 
blood constituents. In this work several approaches based оn affinity interactions 
were tested.  
EXPERIMENTAL 
Serum samples 
Serum samples were obtained from healthy individuals. All samples were taken from 
venous blood 12 h after fasting. The sera were kept frozen at –20 °C until used. This study 
was approved by the local ethical committee in the Institute for the Application of Nuclear 
Energy. 
Immobilised metal-affinity chromatography (IMAC) 
Iminodiacetic acid–agarose (IDA) was purchased from Sigma–Aldrich (Steinheim, 
Germany). A column was packed with 1 mL of gel and washed with distilled water. In order 
to saturate the column with ferric ions, 1.0 mL of 0.10 mol L-1 ferric chloride solution was 
applied. Unbound ions were washed with 5 mL of distilled water and 5 mL of 0.1 % acetic 
acid. Equilibration of the column was realized with dilution buffer: 0.05 mol L-1 MES (2-(N- 
-morpholino)ethanesulphonic acid)/0.5 mol L-1 NaCl buffer pH 5.5.10 Samples (100 µL of 
sera diluted in 900 µL of dilution buffer) were applied to column and circulated for 1 h to 
ensure maximal binding. Unbound material was washed out with 5 mL of MES buffer. 
Elution of the bound molecules was performed using 8 mL of 0.2 mol L-1 phosphate buffer 
(PB) pH 8.0. The column was regenerated using 10 mL of 0.1 mol L-1 borate/1.0 mol L-1 
NaCl buffer pH 10.0 and 10 mL of distilled water, followed by saturation with ferric chloride. 
The collected fractions were analysed by electrophoresis and immunoblotting. 
Immunoaffinity chromatography (IgY-C) 
An IgY-12 column (1.2 mL of microbeads) was purchased from Beckman Coulter 
(Fullerton, USA, Proteomelab IgY-12 High Capacity Proteome Partitioning Kit). According 
to the manufacturer’s description, the matrix with immobilised antibodies enables the binding 
of the 12 most abundant proteins from human plasma: albumin, IgG, IgA, IgM, α1-anti-
trypsin, haptoglobin, fibrinogen, orosomucoid, α2M, HDL (apo A-I and apo A-II) and Tf. 
Samples were prepared by diluting 20 µL of sera with 480 µL of dilution buffer: 10 mmol L-1 
Tris (tris(hydroxymethyl)aminomethane)–HCl/1.0 mol L-1 NaCl buffer pH 7.4, and incubated 
for 15 min at room temperature using a rotator.11 Separation of the unbound proteins was 
performed by centrifugation for 30 s at 2000×g, followed by washing the column three times 
with dilution buffer. The bound proteins were eluted with 500 µL of elution buffer: 0.1 mol L-1 
glycine–HCl, pH 2.5, for 3 min at room temperature using a rotator, separated from gel by 
centrifugation and immediately neutralised with 50 µL of 1 mol L-1 Tris–HCl buffer pH 8.0. 
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The elution was repeated three times. The column was neutralised with 500 µL of 2 mol L-1 
Tris–HCl buffer pH 8.0 and washed with dilution buffer prior to the next chromatographic 
cycle. The collected fractions were analysed by electrophoresis and immunoblotting. 
Lectin affinity chromatography (LAC) 
Eleven agarose-immobilised lectins, purchased from Vector Laboratories (Burlingame, 
CA, USA), were packed in columns: SNA (Sambucus nigra agglutinin), LCA (Lens culinaris 
agglutinin), Con A (lectin from Canavalia ensiformis), PHA-E (Phaseolus vulgaris erythro-
agglutinin), PHA-L (Phaseolus vulgaris leukoagglutinin), RCA-I (Ricinus communis aggluti-
nin I), WGA (wheat germ agglutinin), succinylated WGA, ECL (Erythrina cristagalli lectin), 
MAL (Maackia amurensis lectin) and UEA (Ulex europaeus agglutinin). All buffers and 
hapten sugars were prepared following procedures recommended by the producer. The exact 
composition of each buffer was published elsewhere.12 Serum samples (100 µL) diluted in 
900 µL of the corresponding buffers were circulated through columns for 1 h. Unbound 
material was washed out with 20 mL of the dilution buffers. The elution of bound glyco-
proteins was performed with 7 mL of hapten sugar (0.2–0.5 mol L-1, as suggested by the 
producer) in 0.1 M acetic acid, pH 3.0. The PHA-E and PHA-L columns were eluted using a 
0.1 mol L-1 acetic acid solution. The collected fractions were immediately neutralised using 
2 mol L-1 Tris–HCl buffer pH 8.9, dialysed against distilled water overnight at 4 °C and 
analysed by electrophoresis and immunoblotting. 
Immunoelectrophoresis (IEP) 
Immunoelectrophoresis (IEP) was performed in a standard manner.13 Serum samples (5 
µL) were applied in sample wells, and antibodies in channels (100 µL): polyclonal anti-Tf 
antibodies (INEP, Belgrade, Serbia), and polyclonal anti-IGFBP3 antibodies (DSL, Webster, 
TX, USA). The samples were incubated with antibodies in a humid chamber for 24 h at room 
temperature, to allow immunoprecipitation to occur. 
Co-immunoprecipitation (Co-IP) 
Immunoprecipitation of protein complexes was performed using Pierce® Co-Immu-
noprecipitation Kit (Pierce Biotechnology, Rockford, IL, USA). Following the manufacturer’s 
instructions, AminoLink®Plus Coupling Resin (50 µL of 50 % slurry) was loaded into spin 
columns and 5 µg of anti-IGFBP-3 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) or 10 µg of anti-Tf antibodies (INEP, Belgrade, Serbia) were immobilised. Serum 
samples (10 µL) were diluted in 190 µL of the buffer: 2.5 mmol L-1 Tris/0.15 mol L–1 
NaCl/1.0 mmol L–1 EDTA/1% NP-40/5 % glycerol, pH 7.4 and incubated overnight at 4 °C 
with a resin having immobilised anti-Tf antibodies. Separation of the unbound proteins was 
performed by centrifugation for 30 s at 2000×g, followed by washing the column three times 
with dilution buffer. The bound proteins were eluted with 110 µL of the elution buffer pH 2.8 
(provided within the Kit), separated by centrifugation and immediately neutralised with 2 µL 
of 2 mol L-1 Tris–HCl buffer, pH 8.9. Specifically eluted anti-Tf immunoreactive proteins 
were further incubated with a resin having immobilised anti-IGFBP-3 antibodies, overnight at 
4 °C. The removal of the unbound and the elution of the bound proteins followed the same 
procedure as previously. The collected fractions were analysed by electrophoresis, dot and 
immunoblotting. 
Electrophoresis, dot and Western immunoblotting (WIB) 
Protein fractions obtained by IMAC, IgY-C, LAC, and Co-IP were subjected to dena-
turing non-reducing sodium dodecyl sulphate/polyacrylamide gel electrophoresis (SDS– 
–PAGE) using 10 % gels.14 The separated proteins were transferred to a nitrocellulose mem-
brane and stained with Ponceau S. 
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The WIB procedure was performed using goat polyclonal anti-IGFBP-3 (DSL, Webster, 
TX, USA) and sheep polyclonal anti-Tf (INEP, Belgrade, Serbia) primary antibodies, fol-
lowed by anti-goat secondary antibodies coupled to horseradish peroxidase (Biosource, Ca-
marillo, CA, USA). The immunoreactive proteins were visualised with an enhanced chemi-
luminescence (ECL) reagent kit (Pierce, Minneapolis, MN, USA).14 Molecular mass markers 
were obtained from BioRad Laboratories (Hemel Hempstead, UK). Recombinant IGFBP-3 
(29 kDa, DSL, Webster, TX, USA) and Tf (INEP, Belgrade, Serbia) were used as protein 
markers. 
The presence of IGFBP-3/Tf complexes was also confirmed by dot blotting, employing 
anti-IGFBP-3 and anti-Tf antibodies. 
Ligand-binding assay 
An in-house made matrix, CNBr-activated Sepharose 4B,15,16 was used to immobilise 
sheep anti-Tf antibodies (INEP, Belgrade, Serbia). This immunoaffinity resin was employed 
to test the ability of IGFBP-3 complexed to Tf to bind the ligand. 
Serum samples (100 μL) were incubated with 125I-labelled IGF-II (125I-IGF-II, 300 000 
cpm) at 4 °C overnight, loaded onto a column packed with immunoaffinity resin and re-
circulated for 1 h. The column was left with the sample at 4 °C overnight and the next day, the 
sample was recirculated for a further 1 h. The unbound proteins were washed out with the 
dilution buffer: 0.05 mol L-1 PBS/0.15 mol L-1 NaCl, pH 7.2, and elution of the bound 
fraction was performed using the elution buffer: 0.1 mol L-1 glycine/HCl, pH 3.7. Fractions 
were immediately neutralised with 2 mol L-1 Tris–HCl buffer pH 8.9. The radioactivity and 
the A280 of the collected fractions were measured. 
Ultrafiltration 
Protein fractions containing IGFBP-3/Tf complexes were subjected to ultrafiltration, in 
order to concentrate samples and remove small proteins. Microcon YM-50 filters were used 
(Millipore Corporation, Billerica, USA).  
RESULTS AND DISCUSSION 
In order to isolate IGFBP-3/Tf complexes from human serum, several affi-
nity-based techniques were employed. As IGFBP-3 and Tf are glycosylated17,18 
and IGFBP-3 is also phosphorylated,3 methods based on the following interac-
tions were applied: metal ion–amino acid or phosphate residue,19 lectin–saccha-
ride moiety20–22 and antigen–antibody.23 
In the IMAC method, all IGFBP-3 (Fig. 1A) and Tf (Fig. 1B) immunore-
active species were bound to the matrix: native IGFBP-3 (doublet at ≈45 kDa), 
an IGFBP-3 fragment (≈30 kDa),24 oligomeric/complexed forms of IGFBP-3 
(>80 kDa), as well as Tf (70–80 kDa) and complexes of Tf (>100 kDa). 
In the IgY-C method,25 the immobilised antibodies recognised and bound 
complexes of IGFBP-3 (>100 kDa), whereas native and fragmented IGFBP-3 
species remained among the unbound proteins (Fig. 2A). There were also IGFBP-3 
immunoreactive bands at ≈45 kDa and ≈70 kDa, which might have originated 
from dissociated complexes. Immunoblotting with anti-Tf antibodies (Fig. 2B) 
indicated binding of native Tf, a Tf fragment (≈40 kDa)26 and Tf complexes. In 
the IgY-unbound fraction, anti-Tf antibodies recognised a protein at ≈70 kDa 
(Fig. 2B). It is known that Tf exists in several glycoforms27 and the results of this 
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experiment suggested that the antibodies immobilised on the IgY–C matrix were 
unable to bind the Tf isoform that was less glycosylated. 
 A)  B) 
           
Fig. 1. Immunoblotting of the bound (B) and unbound (U) fractions of serum samples 
obtained after IMAC with А) anti-IGFBP-3 and B) anti-Tf antibodies. The positions 
of the IGFBP-3 monomer and Tf are indicated on the left side, whereas 
the positions of the molecular mass markers are indicated on the right side. 
 A)  B) 
           
Fig. 2. Immunoblotting of the bound (B) and unbound (U) fractions of serum samples 
obtained after IgY-C with A) anti-IGFBP-3 and B) anti-Tf antibodies. 
The positions of the IGFBP-3 monomer and Tf are indicated on the left side, 
whereas the positions of the molecular mass markers are indicated on the right side. 
Lectins are established as an important analytical tool in glycoproteomics. 
As both IGFBP-3 and Tf are glycoproteins, the LAC method was the next me-
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thod of choice. The lectins used in this experiment were those that are known to 
interact with serum glycoproteins.28,29 Of the eleven lectins that were employed 
in the LAC method, only six (PHA-E, RCA-I, Con A, WGA, SNA and LCA) 
bound native IGFBP-3 at ≈45 kDa (Fig. 3A) and five of them (except LCA) bound 
Tf at ≈80 kDa (Fig. 3B). Beside monomer forms (and in some cases fragments), 
higher molecular mass proteins that were both IGFBP-3 and Tf immunoreactive 
were not detected (except at the start). The tested lectins were, therefore, unable 
to bind IGFBP-3/Tf complexes. 
A) 
 
B) 
 
Fig. 3. Immunoblotting of the bound fractions of serum samples obtained after LAC with 
A) anti-IGFBP-3 and B) anti-Tf antibodies. The presented samples were eluted from: 
PHA-E-agarose (lane 1), RCA-I-agarose (lane 2), Con A-agarose (lane 3), WGA-agarose 
(lane 4), SNA-agarose (lane 5) and LCA-agarose (lane 6). The positions of the IGFBP-3 
monomer and Tf are indicated on the left side, whereas the positions of 
the molecular mass markers are indicated on the right side. 
To summarise the above results, none of the applied affinity-chromatogra-
phy methods was able to selectively recognise IGFBP-3/Tf complexes and sepa-
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rate them from the monomeric, oligomeric and fragmented forms of IGFBP-3 
and Tf. As IgY-C seemed the most promising tool, other immunochemical tech-
niques were tested for the isolation of the complexes: immunoelectrophoresis, 
preparative immunoaffinity chromatography and the immunoprecipitation method.30 
In the IEP method, the idea was to analyse immunoprecipitated proteins. The 
IGFBP-3/Tf complexes were expected to travel at a rate different to those of their 
subunits. Since the concentration of Tf in serum31 is much greater than the con-
centration of IGFBP-3,32 the search for complexes was performed in the region 
where free Tf was not expected to be found, but where the reaction with anti-
IGFBP-3 antibodies was positive. Two samples (Fig. 4A, spots 1 and 2), from the 
immunoprecipitating line formed by the interaction of serum with anti-IGFBP-3 
antibodies were analysed. Immunoblotting with anti-IGFBP-3 antibodies revealed 
that an IGFBP-3 fragment and, probably, a dimer (≈70 kDa), were the only im-
munoreactive species in this part of the immunoprecipitated line (Fig. 4B). No 
band at the expected molecular mass of the IGFBP-3/Tf complexes (≈110 kDa) 
was observed. 
A) 
 
 B)  C) 
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D) 
E) 
F) 
 
Fig. 4. A) IEP of a serum sample, with applied antibodies indicated on the right side; selected 
spots from the immunoprecipitating line (1 and 2) were subjected to B) immunoblotting with 
anti-IGFBP-3 antibodies; C) in preparative immunoaffinity chromatography, the amount of 
the eluted proteins (A280) was measured. D) In preparative immunoaffinity chromatography, 
radioactivity of the eluted ligand-binding IGFBP-3/Tf complexes (cpm) was measured; E) dot 
blot and F) Western immunoblotting with anti-IGFBP-3 and anti-Tf antibodies of the isolated 
IGFBP-3/Tf complexes after co-immunoprecipitation. The positions of the IGFBP-3 monomer 
and Tf are indicated on the left side, whereas the positions of the 
molecular mass markers are indicated on the right side. 
Preparative immunoaffinity chromatography is widely appreciated for the 
isolation and purification of immunoreactive species.33 Since the commercial IgY 
matrix was able to bind IGFBP-3/Tf complexes, a matrix for the isolation of the 
anti-Tf antibody reactive molecules was prepared in-house, using CNBr activated 
resin.34 The antibodies were coupled directly. The amount of bound immunore-
active proteins was, unfortunately, very small (Fig. 4C, A280), probably due to an 
improper orientation of the antibodies. The yield of the bound proteins could pos-
sibly be improved by using spacer molecules, such as carbodiimide,34 or protein 
A35 in order to immobilise the antibodies via their C-terminal ends and leave 
their N-terminal, antigen-binding sites, free.36 The same experiment was re-
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peated with serum samples pre-incubated with 125I-IGF-II. Radioactivity mea-
surement (Fig. 4D, cpm) demonstrated that a certain amount of 125I-IGF-II was 
bound to the immobilised anti-Tf antibodies, suggesting that IGFBP-3 in the 
IGFBP-3/Tf complexes retains its ability to bind ligand. 
Finally, a co-immunoprecipitation method was employed, using a commercial 
activated resin to immobilise separately anti-IGFBP-3 and anti-Tf antibodies. 
The immunoprecipitation method is among the most specific techniques to isolate 
a target protein with the least amount of contaminating substances. In this study, 
a double immunoprecipitation was performed. Samples were allowed to interact 
with the immobilised anti-Tf antibodies in the first step and, after elution of the 
bound proteins, this fraction was allowed to interact with anti-IGFBP-3 antibo-
dies. Due to the high affinity of antigen–antibody interactions, the elution neces-
sitated the employment of rather harsh experimental conditions (pH 2.8). In order 
to test whether the IGFBP-3/Tf complexes had survived such conditions, their 
existence was investigated by dot blotting (Fig. 4E). The result demonstrated that 
complexes mostly resisted dissociation. The proteins that were eluted after the 
second step contained almost exclusively IGFBP-3/Tf complexes (Fig. 4F). Frag-
ments (≈30 kDa) were present in minor amounts and they were completely 
removed by ultrafiltration.  
CONCLUSION 
Isolation of the IGFBP-3/Tf complexes from human serum was achieved by 
using an immunoaffinity method, whereas metal- and lectin-affinity techniques 
were unsuccessful. Among several immunochemical approaches, only the double 
immunoprecipitation method selectively separated the complexes from other mo-
lecular forms, such as monomers, oligomers or fragments of IGFBP-3 and Tf. A 
further study of the relationship between IGFBP-3, Tf and Tf saturation with iron 
is expected to elucidate the possible role of IGF/IGFBP-3 in iron metabolism. 
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ИЗВОД 
ИЗОЛОВАЊЕ КОМПЛЕКСА ФОРМИРАНОГ ИЗМЕЂУ ВЕЗУЈУЋЕГ ПРОТЕИНА ЗА 
ИНСУЛИНУ СЛИЧНЕ ФАКТОРЕ РАСТА 3 И ТРАНСФЕРИНА ИЗ ХУМАНОГ СЕРУМА 
ГОРАН МИЉУШ, МИОМИР ПЕТРОВИЋ и ОЛГИЦА НЕДИЋ 
Institut za primenu nuklearne energije – INEP, Univerzitet u Beogradu, 
Banatska 31b, 11080 Beograd-Zemun 
Инсулину  слични  фактори  раста (IGF) имају  важну  улогу  у  расту  ћелија,  њиховој 
диференцијацији и метаболизму. Количину слободног, биoлошки активног IGF регулишу 
IGF везујући протеини (IGFBP). IGFBP-3 је присутан у највећој количини и има способност 
да интерагује са другим протеинима из циркулације, укључујући трансферин (Tf). Да би се 
утврдила могућа улога IGF/IGFBP-3 у метаболизму гвожђа, неопходно је изоловати ком-
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плекс IGFBP-3/Tf. У овој студији је примењено неколико техника заснованих на афинитет-
ним интеракцијама. Резултати су показали да само метода двоструке имунопреципитације са 
анти-Tf, а затим са анти-IGFBP-3 антителима, селективно одваја комплексе од осталих моле-
кулских форми, као што су мономери, олигомери или фрагменти IGFBP-3 и Tf. Овако изо-
ловани комплекс се може даље анализирати у циљу утврђивања односа између IGF/IGFBP-3 
и гвожђа, у структурном и метаболичком смислу. 
(Примљено 31. августа, ревидирано 7. децембра 2011) 
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